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Abstract
Background: Mometasone furoate/formoterol (MF/F) is a novel combination therapy for treatment of persistent
asthma. This noninferiority trial compared the effects of MF/F and fluticasone propionate/salmeterol (FP/S)
combination therapies on pulmonary function and onset of action in subjects with persistent asthma.
Methods: Following a 2- to 4-week run-in period with MF administered via a metered-dose inhaler (MDI) 200 μg
(delivered as 2 inhalations of MF-MDI 100 μg) twice daily (BID), subjects (aged ≥12 y) were randomized to MF/F-
MDI 200/10 μg BID (delivered as 2 inhalations of MF/F-MDI 100/5 μg) or FP/S administered via a dry powder
inhaler (DPI) 250/50 μg (delivered as 1 inhalation) BID for 12 weeks. The primary assessment was change from
baseline to week 12 in area under the curve for forced expiratory volume in 1 second measured serially for 0-12
hours postdose (FEV1 AUC0-12 h). Secondary assessments included onset of action (change from baseline in FEV1 at
5 minutes postdose on day 1) and patient-reported outcomes.
Results: 722 subjects were randomized to MF/F-MDI (n = 371) or FP/S-DPI (n = 351). Mean FEV1 AUC0-12 h change
from baseline at week 12 for MF/F-MDI and FP/S-DPI was 3.43 and 3.24 L × h, respectively (95% CI, -0.40 to 0.76).
MF/F-MDI was associated with a 200-mL mean increase from baseline in FEV1 at 5 minutes postdose on day 1,
which was significantly larger than the 90-mL increase for FP/S-DPI (P < 0.001). The overall incidence of adverse
events during the 12-week treatment period that were considered related to study therapy was similar in both
groups (MF/F-MDI, 7.8% [n = 29]; FP/S-DPI, 8.3% [n = 29]).
Conclusions: The results of this 12-week study indicated that MF/F improves pulmonary function and asthma
control similar to FP/S with a superior onset of action compared with FP/S. Both drugs were safe, improved
asthma control, and demonstrated similar results for other secondary study endpoints.
Trial registration: ClinicalTrials.gov: NCT00424008
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Asthma is a chronic inflammatory disorder of the air-
ways that results in recurrent coughing, chest tightness,
wheezing, and breathlessness [1]. The first line of ther-
apy to relieve symptoms of persistent asthma is inhaled
corticosteroids (ICSs) [1,2]. However, when an ICS
alone is unable to control persistent asthma, the Global
Initiative for Asthma (GINA) [1] and the National
Asthma Education and Prevention Program (NAEPP)
[2] guidelines recommend step-up treatment with an
ICS combined with a long-acting b2-agonist (LABA).
The most recent ICS/LABA combination therapy indi-
cated for the treatment of persistent asthma is mometa-
sone furoate/formoterol delivered via metered-dose
inhaler (MF/F-MDI; Dulera
®/Zenhale
®,S c h e r i n gC o r -
poration, a subsidiary of Merck & Co., Inc., Whitehouse
Station, NJ). Previous studies have demonstrated the
safety and efficacy of MF/F-MDI 100/10 μg twice daily
(BID) [3], MF/F-MDI 200/10 μg BID [4], and MF/F-MDI
400/10 μg BID [5] in subjects previously receiving low-,
medium-, or high-dose ICS monotherapy, respectively. A
long-term safety study [6] also demonstrated that MF/F-
MDI 200/10 and 400/10 μg BID were well tolerated with
safety profiles similar to equivalent doses of a commonly
prescribed ICS/LABA combination, fluticasone propio-
nate/salmeterol (FP/S; Advair
®/Seritide
®, GlaxoSmithK-
line, Research Triangle Park, NC). However, this 1-year
safety study was not powered to compare MF/F and FP/S
with regard to efficacy. The objective of the current study
was to investigate, using an evaluator-blinded, noninfer-
iority design, whether the effects of MF/F-MDI 200/10
μg BID on lung function are noninferior to those of FP/S
250/50 μg BID (delivered via dry powder inhaler [DPI]).
In addition, if noninferiority was demonstrated, the trial
was designed to investigate whether the onset of action
with MF/F-MDI was faster than that with FP/S-DPI.
Methods
This was a multicenter, 12-week,
1 open-label, evaluator-
blinded, active-controlled, noninferiority efficacy and
safety trial in subjects (aged ≥12 y) with uncontrolled per-
sistent asthma previously treated with medium-dose ICS
with or without a LABA. Following a 2- to 4-week run-in
treatment period with MF-MDI 200 μg (delivered as 2
inhalations of MF-MDI 100 μg) BID monotherapy, eligible
subjects were randomized in a 1:1 ratio according to a
computer-generated randomization schedule to MF/F-
MDI 200/10 μg (delivered as 2 inhalations of MF/F-MDI
100/5 μg) BID or FP/S-DPI 250/50 μg (delivered as 1 inha-
lation) BID for 12 weeks (Figure 1). Study visits were
scheduled at screening (days -28 to -14), prebaseline (days
-14 to -7), baseline (day 1), and weeks 1, 2, 4, 8, and 12.
The first dose of study drug was to be taken in the office
under the supervision of a third-party dispenser. Written
instructions on the proper use of the MDI or FP/S-DPI
were provided to subjects. Subjects assigned to the MDI
also used a placebo training inhaler (no DPI placebo train-
ing inhaler matching the FP/S-DPI was available for the
study). The study protocol and amendments received
institutional review board approval and all subjects (or
subject’s legal representation for those under the age of
legal consent) provided written informed consent.
Figure 1 Study Design*. BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; MDI = metered-dose inhaler;
MF = mometasone furoate; MF/F = mometasone furoate/formoterol. *Doses were delivered via 2 actuations of an MDI (MF 100 μg or MF/F
100/5 μg) or 1 actuation of a DPI (FP/S 250/50 μg) BID.
†In the MF/F-MDI 200/10 μg BID treatment group, 42% of subjects discontinued.
‡In the
FP/S-DPI 250/50 μg BID treatment group, 41% of subjects discontinued.
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Key inclusion criteria were ≥12 years of age; asthma
diagnosis for ≥12 months; previous treatment with a
medium-dose ICS, either alone or with a LABA, for ≥12
weeks before screening; stable asthma treatment regi-
men (daily dose unchanged) for ≥2 weeks before screen-
ing; history of ≥2 unscheduled asthma-related visits to a
physician or emergency department within the past
year, or ≥3 unscheduled asthma-related visits within the
past 2 years; forced expiratory volume in 1 second
(FEV1) 60%-90% predicted at screening and baseline; an
increase in absolute FEV1 of ≥12% and ≥200 mL within
15-20 minutes after administration of short-acting b2-
a g o n i s t( S A B A )r e s c u em e d i c ation or peak expiratory
flow (PEF) variability > 20%; and use of ≥12 inhalations
of rescue medication in the final 10 days of the run-in
period.
Key exclusion criteria were > 20% change in absolute
FEV1 between screening and baseline; use of > 8 inhala-
tions per day of a SABA-MDI or ≥2 nebulized treatments
per day of 2.5 mg SABA on any 2 consecutive days
between screening and baseline; 2 consecutive days before
randomization with a decrease in PEF below the run-in
stability limit, calculated over the preceding 7 days; clinical
deterioration of asthma between screening and baseline
that resulted in emergency treatment or hospitalization, or
treatment with asthma medications other than a SABA;
asthma-related emergency department visit or hospital
admission in the past 3 months; current smoker or ex-
smoker (ie, smoked in the previous year or had a cumula-
tive smoking history > 10 pack-years).
Assessments
Lung Function
The study was designed to assess the noninferiority of
MF/F-MDI 200/10 μg BID compared with FP/S-DPI 250/
50 μg BID in their effect on lung function as measured by
the change from baseline (mean of 2 predose measure-
ments on day 1) to week 12 (last observation carried for-
ward [LOCF]) in area under the curve (AUC) in FEV1
measured serially over 0-12 hours postdose (FEV1 AUC0-
12 h). As a key secondary assessment, the study was also
powered to assess whether MF/F-MDI 200/10 μg BID was
superior to FP/S-DPI 250/50 μg BID in onset of action (ie,
change from baseline in FEV1 at 5 minutes postdose on
day 1) if lung function noninferiority was demonstrated.
Serial spirometry assessments of FEV1 were performed
after the previous evening’sd o s ea tb a s e l i n e( d a y1 )a n d
the final visit (week 12) according to the following sche-
dule: 30 minutes and immediately before the subject’s
morning (AM) dose of study medication; 5, 15, and 30
minutes after the AM dose; and 1, 2, 3, 4, 6, 8, 10, 11, and
12 hours after the AM dose. Additional secondary
assessments included changes from baseline in trough
FEV1 and AM PEF at each visit and week 12 (LOCF).
Asthma Control, Quality of Life, and Symptoms
Changes from baseline to week 12 (LOCF) in total Asthma
Control Questionnaire (ACQ) [7] score and the propor-
tion of symptom-free (ie, total asthma symptom score = 0
[range, 0 = none to 3 = severe]) days and nights combined
were key secondary assessments. Changes from baseline in
total Asthma Quality of Life Questionnaire With Standar-
dized Activities (AQLQ[S]) [8] score, 24-hour symptom
score, and proportion of nocturnal awakenings due to
asthma requiring SABA rescue medication (where baseline
was the proportion of nights with nocturnal awakenings
[days -7 to 1] before the first treatment dose) were addi-
tional secondary assessments.
Clinically Judged Asthma Deteriorations
The incidence of clinically judged asthma deteriorations,
defined as asthma resulting in emergency treatment, hos-
pitalization, or treatment with additional (excluded)
asthma medication (eg, systemic glucocorticoids) were
recorded throughout the study.
Safety
Safety was assessed by monitoring adverse events (AEs),
clinical laboratory tests, physical examinations (including
oropharyngeal examination), vital signs, and electrocardio-
gram (ECG) recordings throughout the study.
Statistical Analyses
Assuming a dropout rate of 5%, a sample size of 332
subjects for each treatment group was to be enrolled
to ensure that 315 subjects would be available for the
test of noninferiority based on the change from base-
line to week 12 (LOCF) in FEV1 AUC0-12 h at 80%
power, assuming a standard deviation of 6.7 L × h.
Noninferiority for the primary variable was achieved
when the lower bound of a 2-sided 95% confidence
interval of the treatment difference (MF/F-MDI - FP/
S-DPI) exceeded -1.5 L × h in the change from base-
l i n et ow e e k1 2( L O C F )i nF E V 1 AUC0-12 h.T h e
selected lower bound of -1.5 L × hr was one-half of an
estimated treatment difference of an active treatment
versus placebo (3.1 L × h).
Changes from baseline in all assessments were ana-
lyzed by analysis of covariance, using treatment and
study site as fixed effects and the corresponding baseline
value for that assessment as a continuous covariate.
Results
Demographics and Disposition
A total of 722 subjects were randomized to receive MF/
F-MDI 200/10 μg BID (n = 371) or FP/S-DPI 250/50 μg
BID (n = 351). Demographic and baseline characteristics
were balanced across the 2 treatment groups. Most
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86%; Table 1); mean age was 44.9 years. Median dura-
tion of asthma was 12 years. Before participation in the
study, most subjects were receiving 1 of the following:
budesonide (monotherapy or in combination), beclo-
methasone (monotherapy), or fluticasone (monotherapy
or in combination). Subjects had moderate persistent
asthma that was uncontrolled after the MF 200-μgB I D
run-in period, based on FEV1 (ie, 60%-80% predicted)
and ACQ (ie, score ≥1.5) findings as related to defini-
tions from the NAEPP [2].
The percentages of subjects who discontinued the trial
t h r o u g hw e e k1 2w e r e4 2 %a n d4 1 %i nt h eM F / F - M D I
200/10 μg BID and FP/S-DPI 250/50 μg BID treatment
groups, respectively. Administrative reasons
2 were the
most common cause of subject discontinuation in both
treatment groups (25.6% and 24.2%). The mean times to
administrative discontinuation were 76.0 days in the MF/
F-MDI and 80.2 days in the FP/S-DPI groups, close to
the 85-day treatment duration scheduled for a 12-week
study. Fully 81.3% of subjects (579/712) remained in the
trial long enough to qualify for the Week 12 observed
cases evaluation window, compared to the primary end-
point last-observation-carried-forward into Week 12,
which includes those who discontinued earlier. Disconti-
nuation as the result of an AE represented only a small
proportion of subjects (approximately 2%) in each
treatment group, while discontinuation for treatment fail-
ure represented 5% of subjects in each treatment group.
Lung Function
At week 12 (LOCF), FEV1 AUC0-12 h for MF/F-MDI and
FP/S-DPI was 3.43 vs 3.24 L × h, respectively (95% CI,
-0.40 to 0.76), indicating that MF/F-MDI was not infer-
ior to FP/S-DPI; noninferiority was also demonstrated
on day 1 (3.66 vs 3.29 L × h [95% CI, -0.11 to 0.84])
and week 12 (3.45 vs 3.33 L × h [95% CI, -0.56 to
0.79]). Mean FEV1 AUC0-12 h values at week 12 (LOCF)
corresponded to standardized increases from baseline of
0.29 L (12.7%) for MF/F-MDI and 0.27 L (12.1%) for
FP/S-DPI when averaged across the 12-hour serial spiro-
metry evaluation period (Figure 2).
Analysis of onset-of-action characteristics revealed
that the effect of MF/F-MDI occurred significantly faster
than the effect of FP/S-DPI (Figure 3). At 5 minutes
postdose (the first scheduled measurement) on day 1 of
the study, MF/F-MDI was associated with a 200-mL
least-squares (LS) mean increase from baseline in FEV1
versus a 90-mL increase with FP/S-DPI (P <0 . 0 0 1 ) .
When adjusting for multiplicity (using P < 0.0125), the
rapid, persistent effect of MF/F-MDI on FEV1 was sig-
nificantly greater than the effect of FP/S-DPI for all time
points measured up to 30 minutes postdose (P < 0.001;
Figure 3).
Table 1 Subject Demographics and Baseline Characteristics
Demographic or Characteristic MF/F-MDI
200/10 μg BID (n = 371)
FP/S-DPI
250/50 μg BID (n = 351)
Sex, n (%)
Female 239 (64) 220 (63)
Race, n (%)
White 323 (87) 301 (86)
Mean age, y (range) 44.8 (12-82) 45.1 (12-80)
Duration of asthma, y
Mean 15.0 15.9
Median 11.0 13.0
Prior ICS use, n (%)* 225 (61) 188 (54)
Prior ICS/LABA use, n (%)*
Budesonide/formoterol 59 (16) 59 (17)
Fluticasone/salmeterol 104 (28) 115 (33)
Mean FEV1 at baseline
L 2.30 2.37
Percentage predicted 73.8 74.4
Mean total ACQ score
† 1.80 1.80
Mean total AQLQ(S) score
‡ 5.14 5.14
ACQ = Asthma Control Questionnaire; AQLQ(S) = Asthma Quality of Life Questionnaire With Standardized Activities; BID = twice daily; DPI = dry powder inhaler;
FEV1 = forced expiratory volume in 1 s; FP/S = fluticasone propionate/salmeterol; ICS = inhaled corticosteroid; LABA = long-acting b2-agonist; MDI = metered-
dose inhaler; MF/F = mometasone furoate/formoterol.
*Subjects could have received multiple types of ICS monotherapy and combination ICS/LABA therapy in the 3 months before screening.
†ACQ score based on a 7-point scale that ranged from 0 (best asthma control) to 6 (worst asthma control).
‡AQLQ(S) score based on a 7-point scale that ranged from 1 (worst quality of life) to 7 (best quality of life)
Bernstein et al. Allergy, Asthma & Clinical Immunology 2011, 7:21
http://www.aacijournal.com/content/7/1/21
Page 4 of 9Baseline LS mean trough FEV1 values were 2.31 and
2.39 L in the MF/F-MDI and FP/S-DPI groups, respec-
tively. Changes from baseline in trough FEV1 were not
significantly different between groups at week 12
(LOCF) (0.14 and 0.17 L, respectively) or any time dur-
ing the 12-week treatment period.
Both groups had similar baseline LS mean AM PEF
values (MF/F-MDI, 360.3 L/min; FP/S-DPI, 363.3 L/
min), and both treatments resulted in stable and positive
AM PEF changes from baseline. There were no signifi-
cant differences between treatments in change from
baseline LS mean AM PEF at any week or week 12
(LOCF) (MF/F-MDI, 21.3 L/min [6.9%]; FP/S-DPI, 23.0
L/min [7.9%]).
Asthma Control, Quality of Life, and Symptoms
At week 4 and week 12 (LOCF), MF/F-MDI was nonin-
ferior to FP/S-DPI in LS mean total ACQ and AQLQ(S)
score changes from baseline (Figure 4). In both groups,
ACQ scores improved to levels that were below the
uncontrolled threshold. In addition, ACQ and AQLQ(S)
score changes achieved a minimally important difference
(MID; ≥0.5) [9,10] in both groups.
Both groups had the same LS mean baseline propor-
tion of nights with nocturnal awakenings due to
asthma that required the use of a SABA (0.23). Both
treatments reduced this proportion by > 65% at week
12 (LOCF) (MF/F-MDI, -0.14 [-65.5%]; FP/S-DPI, -0.16
[-69.8%]); there was no significant difference between
the groups.
Total LS mean 24-hour asthma symptom scores were
similar between the groups (MF/F-MDI, 1.87; FP/S-DPI,
1.89). Both treatments improved (ie, reduced) LS mean
symptom scores by ≥40% at week 12 (LOCF) (MF/F-
MDI, -0.82 [-40.0%]; FP/S-DPI, -0.91 [-49.9%]); there
was no significant difference between the groups.
MF/F-MDI was found to be noninferior to FP/S-DPI
in the proportion of symptom-free days and nights; both
treatment groups demonstrated improvements from
baseline (Figure 5).
Clinically Judged Asthma Deteriorations
The percentage of subjects who experienced a clinically
judged asthma deterioration (ie, a deterioration of
asthma requiring further treatment; see methods) was
the same in both treatment groups (MF/F-MDI, 5.7% [n
= 21]; FP/S-DPI, 5.7% [n = 20]).
Safety
The incidence of AEs during the 12-week treatment per-
iod that were considered related to study therapy was
similar in both groups (MF/F-MDI, 7.8% [n = 29]; FP/S-
DPI, 8.3% [n = 29]). The most common treatment-related
AEs were dysphonia (MF/F-MDI, 1.6% [n = 6]; FP/S-DPI,
2.8% [n = 10]), headache (MF/F-MDI, 0.8% [n = 3]; FP/S-
DPI, 0.9% [n = 3]), oropharyngeal pain (MF/F-MDI, 1.1%
[n = 4]; FP/S-DPI, 0.6% [n = 2]), and oropharyngeal can-
didiasis (MF/F-MDI, 0.5% [n = 2]; FP/S-DPI, 0.6% [n =
2]). Serious AEs occurred infrequently (MF/F-MDI, 1.3%
[n = 5]; FP/S-DPI, 1.4% [n = 5]); only 1 serious AE (ven-
tricular extrasystoles, MF/F-MDI) was considered prob-
ably treatment related. No life-threatening AEs were
reported, and no subjects died during the study. No clini-
cally relevant changes in laboratory values, mean vital
signs, or ECG measurements were observed.
Figure 2 Serial FEV1 (0-12 h) and Standardized FEV1 AUC0-12 h
at Week 12 (LOCF). AUC = area under the curve; BID = twice daily;
DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1
second; FP/S = fluticasone propionate/salmeterol; LOCF = last
observation carried forward; MDI = metered-dose inhaler; MF/F =
mometasone furoate/formoterol.
Figure 3 Onset of Action: Serial FEV1 (0-1 h) at Day 1.B I D=
twice daily; DPI = dry powder inhaler; FEV1 = forced expiratory
volume in 1 second; FP/S = fluticasone propionate/salmeterol; MDI
= metered-dose inhaler; MF/F = mometasone furoate/formoterol. *P
< 0.001.
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This study in adult and adolescent subjects with persis-
tent asthma uncontrolled on medium-dose ICS mono-
therapy demonstrated that treatment with MF/F-MDI
200/10 μg BID improved lung function and other
patient-reported outcomes similar to FP/S-DPI 250/50
μg BID with an onset of action superior to FP/S-DPI.
Although stable lung function was demonstrated during
the open-label run-in period, subjects were still uncon-
trolled at baseline (ie, total ACQ score ≥1.5), indicating
that medium-dose MF alone was suboptimal for treating
this subject population. Two key observations can be
taken from the lung function results regarding the effi-
cacy of MF/F over 12 weeks of treatment. First, treatment
with MF/F-MDI 200/10 μg BID was noninferior com-
pared with FP/S-DPI 250/50 μgB I Db a s e do nF E V 1
AUC0-12 h at week 12 (LOCF). Second, a significant
(≥200 mL from baseline) bronchodilator effect of the
MF/F combination was observed as early as 5 minutes
postdose, which was superior to FP/S through 30 minutes
on day 1. This result was expected given the known char-
acteristics of these ICS/LABA combination constituents.
Previous studies have demonstrated the efficacy of MF
[11-14] and FP [15-17] monotherapy in improving lung
function outcomes in patients with asthma. Although
LABA monotherapy should not be used to treat asthma
[18], formoterol and salmeterol have also been shown to
be effective in improving lung function outcomes [19].
However, formoterol is associated with a faster onset of
action than salmeterol [20,21]. As such, it does not seem
surprising that MF/F was associated with a faster onset of
action than FP/S in the current study.
As recently reviewed by Murphy and Bender [22], sev-
eral surveys have indicated that rapid onset of action is
ah i g h l yd e s i r a b l ea t t r i b u t eo fa s t h m at h e r a p yf r o ma
patient perspective. The perception that controller medi-
cation is working immediatelyi sas t r o n gp r e d i c t o ro f
overall treatment satisfaction and may lead to improved
medication adherence [22]. However, although the pre-
sent study demonstrated greater improvements in pul-
monary function 5-30 minutes postdose for the MF/F-
MDI group compared with the FP/S-DPI group, it did
not measure corresponding symptom scores during that
time period. Thus, the clinical relevance of the faster
onset of action with MF/F-MDI compared with FP/S-
DPI has not been determined.
A tw e e k1 2( L O C F ) ,aM I Di nt o t a lA C Qs c o r ew a s
achieved in both treatment groups and both treatments
also shifted patients to the “controlled” [23] ACQ score
range. Other secondary efficacy results (eg, improve-
ments in the AQLQ[S] total score) further indicated
that MF/F-MDI 200/10 μg BID is noninferior to FP/S-
DPI 250/50 μg BID and that both treatments improved
asthma outcomes compared with baseline
measurements.
A review of the safety data indicated that both treat-
ments were well tolerated. The number and type of AEs
reported in this study were not unexpected and did not
raise any new safety concerns with regard to MF/F-MDI
or FP/S-DPI. The most common treatment-related AE
reported was dysphonia, which is a known side effect of
ICS treatment [24].
This study was originally scheduled for 1 year and was
stopped early due to protracted enrollment period,
which resulted in a longer than expected study duration.
At the termination of the study, 12-week data were
available for 81.3% of patients (579 of the 712 patients
originally enrolled in the study), and 40% of noncomple-
tion occurred after the termination of the study. There-
fore, most of these discontinuations were a product of
early trial termination. Yet because the mean times to
administrative discontinuation were approximately 80
days in each treatment group–close to the 85-day treat-
ment duration scheduled for a 12-week study–and
because a large proportion of subjects (81.3%) remained
in the trial long enough to qualify for the Week 12
observed cases evaluation window, the integrity of the
population for noninferiority evaluation was not com-
promised. Similarly, the proportions of discontinuations
owing to reasons other than administrative are similar
to those for other MF/F-MDI studies [3-5].
This trial was of 12 weeks’ duration and, as such, does
not provide insight into the longer-term efficacy and
safety of MF/F-MDI. The longer-term safety of MF/F-
MDI has been demonstrated by Maspero et al [6]. The
trial was of an open-label design and is, therefore, sub-
ject to the typical limitations inherent with open-label
study. However, an open-label randomized design with
frequent, uniform study visits and robust clinical end-
points, such as that used for this study, can be appropri-
ate for comparing similar treatments to determine
noninferiority. In this context, it is of interest to note
the primary analysis of FEV1 A U Ca te n d p o i n tf a v o r e d
MF/F-MDI by 20 mL over FP/S-DPI in a design setting
that usually favors the comparator marketed product.
While the study was open-label, subjects were expected
to be more familiar with the treatment administration of
FP/S-DPI than the use of the MF/F-MDI test product.
An important consideration with this noninferiority
design was the demonstration of assay sensitivity.
Thus, the subject’s own treatment was discontinued at
screening, and a run-in period was carried out during
which subjects had to demonstrate a degree of asthma
d e t e r i o r a t i o no nM Fm o n o t h e r a p y .T h er e s u l t ss h o w
that the study population was appropriately treated
with combination therapy and provided assurance that
Bernstein et al. Allergy, Asthma & Clinical Immunology 2011, 7:21
http://www.aacijournal.com/content/7/1/21
Page 6 of 9the study population was sensitive enough to detect a
potential difference between the MDI and DPI formu-
lations by demonstrating that subjects were responsive
to changes in treatment. Therefore, the results indicate
that subjects not well controlled on ICS monotherapy
will improve lung function and asthma control to the
same degree when treated with either combination. It
is also important to note that the current study was
adequately powered to test for superiority of the onset
of action endpoint, and previous trials [3-5] have
demonstrated the superiority of MF/F compared with
placebo, MF, and/or formoterol for various efficacy
assessments.
Conclusion
In conclusion, the results of this study indicated that
MF/F-MDI 200/10 μg BID is noninferior based on FEV1
AUC0-12 h and superior in onset of action to FP/S-DPI
250/50 μg BID over 12 weeks of treatment. Both combi-
nations were safe, improved asthma control, and
Figure 4 Mean Total ACQ* (top) and AQLQ(S)
† (bottom) Scores. ACQ = Asthma Control Questionnaire; AQLQ(S) = Asthma Quality of Life
Questionnaire With Standardized. Activities; BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; LOCF = last
observation carried forward; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol; MID = minimally important difference. *ACQ
score based on a 7-point scale that ranged from 0 (best asthma control) to 6 (worst asthma control).
†AQLQ(S) score based on a 7-point scale
that ranged from 1 (worst quality of life) to 7 (best quality of life).
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endpoints.
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